Evotec SE (EVO) Current Deferred Revenue (2009 - 2026)
Evotec SE (EVO) reported Current Deferred Revenue of $154630.9 for Q1 2026, down 24.37% on a YoY basis from $204456.9 in Q1 2025, and down 8.59% sequentially from $169163.5 in Q4 2025.
Evotec SE (EVO) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Current Deferred Revenue data on file, last reported at $154630.9 in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 24.37% year-over-year to $154630.9; the trailing twelve-month figure through Mar 2026 stood at $154630.9 (down 24.37% YoY), and the FY2025 full-year result was $169163.5, down 99.85% from the prior year.
- Current Deferred Revenue fell to $154630.9 in Q1 2026, from $169163.5 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $125.4 million in Q4 2022 to a low of -$142951.5 in Q2 2022.
- A 5-year average of $28.8 million and a median of $190800.6 in 2025 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue soared 153.44% in 2022 and slumped 99.85% in 2025, its largest moves.
- Tracing EVO's Current Deferred Revenue over 5 years: stood at $125.4 million in 2022, then decreased by 16.28% to $105.0 million in 2023, then grew by 8.49% to $113.9 million in 2024, then tumbled by 99.85% to $169163.5 in 2025, then slipped by 8.59% to $154630.9 in 2026.
- Business Quant data shows EVO's Current Deferred Revenue at $154630.9 in Q1 2026, $169163.5 in Q4 2025, and $197969.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154,630.91 |
| Dec 31, 2025 | 169,163.46 |
| Sep 30, 2025 | 197,968.96 |
| Jun 30, 2025 | 183,632.16 |
| Mar 31, 2025 | 204,456.88 |
| Dec 31, 2024 | 113.91 Mn |
| Sep 30, 2024 | 228,656.99 |
| Dec 31, 2023 | 105.00 Mn |
| Dec 31, 2022 | 125.41 Mn |
| Sep 30, 2022 | 181,458.12 |
| Jun 30, 2022 | -142,951.45 |
| Mar 31, 2022 | 126,672.65 |
| Dec 31, 2021 | 128.19 Mn |
| Sep 30, 2021 | 71,598.07 |
| Dec 31, 2020 | 79.26 Mn |
| Sep 30, 2010 | 6,226.52 |
| Jun 30, 2010 | 6,318.09 |
| Mar 31, 2010 | 6.14 |
| Dec 31, 2009 | 8,096.93 |
| Jun 30, 2009 | 9.79 Mn |